The immunologic aspects of poxvirus oncolytic therapy

被引:0
|
作者
Andrea Worschech
D. Haddad
D. F. Stroncek
E. Wang
Francesco M. Marincola
Aladar A. Szalay
机构
[1] San Diego Science Center,Genelux Corporation
[2] University of Wuerzburg,Institute for Biochemistry, Virchow Center for Experimental Biomedicine
[3] Clinical Center,Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine and Center for Human Immunology (CHI)
[4] National Institutes of Health (NIH),Department of Surgery
[5] Memorial Sloan-Kettering Cancer Center,Cell Therapy Section, Department of Transfusion Medicine
[6] Clinical Center,undefined
[7] NIH,undefined
来源
Cancer Immunology, Immunotherapy | 2009年 / 58卷
关键词
Vaccinia virus; Oncolytic therapy; Innate immunity; Tumor rejection;
D O I
暂无
中图分类号
学科分类号
摘要
The concept of using replicating oncolytic viruses in cancer therapy dates to the beginning of the twentieth century. However, in the last few years, an increasing number of pre-clinical and clinical trials have been carried out with promising preliminarily results. Novel, indeed, is the suggestion that viral oncolytic therapy might not operate exclusively through an oncolysis-mediated process but additionally requires the “assistance” of the host’s immune system. Originally, the host’s immune response was believed to play a predominant obstructive role against viral replication, hence limiting the anti-tumor efficacy of viral vectors. Recent data, however, suggest that the immune response may also play a key role in promoting tumor destruction in association with the oncolytic process. In fact, immune effector pathways activated during oncolytic virus-induced tumor rejection seem to follow a similar pattern to those observed when the broader phenomenon of immune-mediated tissue-specific rejection occurs in other immune-related pathologies. We recently formulated the “Immunologic Constant of Rejection” hypothesis, emphasizing commonalties in transcriptional patterns observed when tissue-destruction occurs: whether with a favorable outcome, such as in tumor rejection and pathogen clearance; or a destructive one, such as in allograft rejection or autoimmunity. Here, we propose that a similar mechanism induces clearance of virally infected tumors and that such a mechanism is primarily dependent on innate immune functions.
引用
收藏
页码:1355 / 1362
页数:7
相关论文
共 50 条
  • [31] Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis
    Hu, Jinqing
    Wang, Huaiyuan
    Gu, Jinfa
    Liu, Xinyuan
    Zhou, Xiumei
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 50 (10) : 1018 - 1027
  • [32] Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus
    Burgess, Hannah M.
    Pourchet, Aldo
    Hajdu, Cristina H.
    Chiriboga, Luis
    Frey, Alan B.
    Mohr, Ian
    MOLECULAR THERAPY-ONCOLYTICS, 2018, 8 : 71 - 81
  • [33] Clinical aspects of immunologic monitoring
    Chatenoud, L
    Roche, A
    Lavenne, D
    Dubray, C
    Bach, JF
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (04) : 1812 - 1813
  • [34] IMMUNOLOGIC ASPECTS OF RHEUMATOID ARTHRITIS
    BOLLET, AJ
    POSTGRADUATE MEDICINE, 1966, 40 (04) : 391 - &
  • [35] Some immunologic aspects of leukemia
    Hueper, WC
    Russell, M
    ARCHIVES OF INTERNAL MEDICINE, 1932, 49 (01) : 113 - 122
  • [36] IMMUNOLOGIC AND ADRENERGIC ASPECTS OF ASTHMA
    DOCKHORN, RJ
    ANNALS OF ALLERGY, 1971, 29 (10): : 539 - +
  • [37] IMMUNOLOGIC ASPECTS OF RENAL TRANSPLANTATION
    BRAUN, WE
    SURGICAL CLINICS OF NORTH AMERICA, 1971, 51 (05) : 1161 - &
  • [38] IMMUNOLOGIC ASPECTS OF ADRENOCORTICAL INSUFFICIENCY
    WUEPPER, KD
    WEGIENKA, LC
    FUDENBERG, HH
    AMERICAN JOURNAL OF MEDICINE, 1969, 46 (02): : 206 - +
  • [39] THE IMMUNOLOGIC ASPECTS OF ALLERGIC CONDITIONS
    SPAIN, WC
    ANNALS OF INTERNAL MEDICINE, 1953, 38 (02) : 188 - 198
  • [40] IMMUNOLOGIC ASPECTS OF BIOGENESIS OF ERYTHROPOIETIN
    SCHOOLEY, JC
    ZANJANI, ED
    GORDON, AS
    BLOOD-THE JOURNAL OF HEMATOLOGY, 1970, 35 (03): : 276 - +